Phoenix Financial Ltd. grew its position in AstraZeneca Plc (NYSE:AZN – Free Report) by 21.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,453 shares of the company’s stock after buying an additional 4,088 shares during the period. Phoenix Financial Ltd.’s holdings in AstraZeneca were worth $3,787,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in AZN. Channel Wealth LLC raised its position in AstraZeneca by 2.8% in the third quarter. Channel Wealth LLC now owns 18,324 shares of the company’s stock valued at $2,959,000 after purchasing an additional 501 shares during the period. Hamel Associates Inc. acquired a new position in shares of AstraZeneca in the 3rd quarter valued at $646,000. Moors & Cabot Inc. acquired a new position in shares of AstraZeneca in the 3rd quarter valued at $1,155,000. William Blair Investment Management LLC purchased a new position in shares of AstraZeneca during the 3rd quarter worth $90,809,000. Finally, Allworth Financial LP grew its holdings in shares of AstraZeneca by 313.0% during the 3rd quarter. Allworth Financial LP now owns 33,413 shares of the company’s stock worth $5,395,000 after purchasing an additional 25,322 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.
AstraZeneca Trading Up 0.1%
Shares of NYSE AZN opened at $184.66 on Monday. AstraZeneca Plc has a twelve month low of $153.41 and a twelve month high of $212.71. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51. The stock has a fifty day simple moving average of $168.82 and a 200-day simple moving average of $180.20. The stock has a market capitalization of $286.40 billion, a PE ratio of 26.12, a PEG ratio of 1.43 and a beta of 0.24.
AstraZeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The firm had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same quarter in the previous year, the business earned $2.38 EPS. The company’s quarterly revenue was up 6.5% compared to the same quarter last year. On average, equities analysts forecast that AstraZeneca Plc will post 10.22 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. CICC Research assumed coverage on AstraZeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective for the company. Weiss Ratings raised shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 26th. Nordea Equity Research raised shares of AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. Zacks Research upgraded shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Finally, Royal Bank Of Canada initiated coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $206.67.
View Our Latest Stock Report on AZN
AstraZeneca Company Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Recommended Stories
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
